SLC5A2 and type 2 diabetes mellitus: The finding that SGLT2 inhibitors are associated with a reduced risk of cardiovascular death or hospitalization for HF even in metformin-naïve patients with T2D at high cardiovascular risk or with CVD [17] supports the updated guidelines that recommend SGLT2 inhibitors as first-line therapy in this patient population [1, 2].